Sanofi, a French pharmaceutical firm entered into a partnership with Google Life Sciences several weeks ago, to expand its research into treatments for diabetes.
Sanofi already has experience in the connected health. It has designed a connectable measuring device to an Apple iPhone and smartphone applications , as Glucocompteur.
Contact lenses are an example of technologies that google has already set up in the fight against diabetes. Google has been fighting to improve the lives of sufferers for a long time.
The diabetes market is one of the most lucrative and one of the most competitive in the pharmaceutical sector. Evaluate Pharma, a consultancy, estimates that sales of anti- diabetics have reported over 41 billion dollars ( 36.3 billion euros ) to the laboratories in 2014.
Sanofi and Google are going to share their expertise in science and tech to work on more integrated ways to collect, analyze and understand information.
The purpose of thisfunion is to facilitate the life of the patients and to lower the cost of treatments
What is diabetes ?
When you eat, your body turns food into sugars, or glucose. At that point, your pancreas is supposed to release insulin.
Insulin serves as a “key” to open your cells, to allow the glucose to enter — and allows you to use the glucose for energy.
But with diabetes, this system does not work.
The latest edition IDF Diabetes Atlas estimates that in 2035 people living with diabetes will expand from 382 million to 592 million people.
The new collaboration centers on improving care and outcomes for patients suffering from type 1 and type 2 diabetes, pairing Sanofi’s treatments and devices with Google’s analytics, miniaturized electronics and low-power chips.
Type 1 and type 2 diabetes are the most common forms of the disease, but there are also other kinds, such as gestational diabetes, which occurs during pregnancy, as well as other forms.
Both companies will workdon developing innovating tools to improve patient care and find new treatments thatdcombine blood glucose and hemoglobin A1c level indicators, patient-centric information, medication routines and sensor devices.
Researchers wish that the combined technology, sensors, analytics and digital applications will improve how blood sugars are managed, to deliver a better quality of life that lowers complications. Last but not the least hope is to succeed to reduces the costs and treatment barriers.
Only two days after its Alphabet announcement, Google teamed up with healthcare firm Dexcom to build tiny blood glucose monitoring devices for diabetics.
Terms of the partnership between Google Life Sciences and Sanofi were not disclosed.
Judith HALLEL
Etudiante en Master 2 Gestion et Droit de l’Economie du Numérique à l’Université de Strasbourg, le droit de la propriété intellectuelle et le monde du numérique sont des domaines pour lesquels j’éprouve un fort intérêt. Ces matières sont des atouts à l’ère du numérique, de la communication et des réseaux sociaux.
